Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M. Molinari A, et al. Among authors: poggialini f. Bioorg Med Chem Lett. 2018 Nov 15;28(21):3454-3457. doi: 10.1016/j.bmcl.2018.09.024. Epub 2018 Sep 20. Bioorg Med Chem Lett. 2018. PMID: 30262428
Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment.
Di Maria S, Picarazzi F, Mori M, Cianciusi A, Carbone A, Crespan E, Perini C, Sabetta S, Deplano S, Poggialini F, Molinari A, Aronne R, Maccioni E, Maga G, Angelucci A, Schenone S, Musumeci F, Dreassi E. Di Maria S, et al. Among authors: poggialini f. Bioorg Chem. 2022 Nov;128:106071. doi: 10.1016/j.bioorg.2022.106071. Epub 2022 Aug 1. Bioorg Chem. 2022. PMID: 35932498
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme.
Poggialini F, Vagaggini C, Brai A, Pasqualini C, Crespan E, Maga G, Perini C, Cabella N, Botta L, Musumeci F, Frosini M, Schenone S, Dreassi E. Poggialini F, et al. Pharmaceutics. 2023 Jan 30;15(2):453. doi: 10.3390/pharmaceutics15020453. Pharmaceutics. 2023. PMID: 36839775 Free PMC article.
Discovery and Optimization of a Novel Macrocyclic Amidinourea Series Active as Acidic Mammalian Chitinase Inhibitors.
Balestri LJI, Trivisani CI, Orofino F, Fiorucci D, Truglio GI, D'Agostino I, Poggialini F, Botta L, Docquier JD, Dreassi E. Balestri LJI, et al. Among authors: poggialini f. ACS Med Chem Lett. 2023 Mar 21;14(4):417-424. doi: 10.1021/acsmedchemlett.2c00472. eCollection 2023 Apr 13. ACS Med Chem Lett. 2023. PMID: 37077400 Free PMC article.
Progress towards Adjuvant Development: Focus on Antiviral Therapy.
Brai A, Poggialini F, Pasqualini C, Trivisani CI, Vagaggini C, Dreassi E. Brai A, et al. Among authors: poggialini f. Int J Mol Sci. 2023 May 25;24(11):9225. doi: 10.3390/ijms24119225. Int J Mol Sci. 2023. PMID: 37298177 Free PMC article. Review.
28 results